Aortic valvular heart disease: is there a place for angiotensin-converting-enzyme inhibitors?

References

• Nkomo VT, Gardin JM, Skelton TN, Gottdiener JS, Scott CG, Enriquez-Sarano M. Burden of valvular heart diseases: a population-based study. Lancet 368(9540), 1005–1011 (2006).
   PubMed Web of Science ®Google Scholar
• Freeman RV, Otto CM. Spectrum of calcific aortic valve disease: pathogenesis, disease progression, and treatment strategies. Circulation 111(24), 3316–3326 (2005).
   PubMed Web of Science ®Google Scholar
• Lebowitz NE, Bella JN, Roman MJ et al. Prevalence and correlates of aortic regurgitation in American Indians: the Strong Heart Study. J. Am. Coll. Cardiol. 36(2), 461–467 (2000).
   PubMed Web of Science ®Google Scholar
• Singh JP, Evans JC, Levy D et al. Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study). Am. J. Cardiol. 83(6), 897–902 (1999).
   PubMed Web of Science ®Google Scholar
• Nightingale AK, Horowitz JD. Aortic sclerosis: not an innocent murmur but a marker of increased cardiovascular risk. Heart 91(11), 1389–1393 (2005).
   Google Scholar
• Cosmi JE, Kort S, Tunick PA et al. The risk of the development of aortic stenosis in ‘patients with benign aortic valve’ thickening. Arch. Intern. Med. 162(20), 2345–2347 (2002).
   PubMedGoogle Scholar
• Chambers J. Aortic stenosis. BMJ 330(7495), 801–802 (2005).
   Google Scholar
• Leon MB, Smith CR, Mack M et al.; PARTNER Trial Investigators. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N. Engl. J. Med. 363(17), 1597–1607 (2010).
   PubMed Web of Science ®Google Scholar
• Otto CM. Valvular aortic stenosis: disease severity and timing of intervention. J. Am. Coll. Cardiol. 47(11), 2141–2151 (2006).
   PubMed Web of Science ®Google Scholar
• Pellikka PA, Sarano ME, Nishimura RA et al. Outcome of 622 adults with asymptomatic, hemodynamically significant aortic stenosis during prolonged follow-up. Circulation 111(24), 3290–3295 (2005).
   PubMed Web of Science ®Google Scholar
• Ngo DT, Sverdlov AL, Horowitz JD. Prevention of aortic valve stenosis: a realistic therapeutic target? Pharmacol. Ther. 135(1), 78–93 (2012).
   PubMedGoogle Scholar
• Sverdlov AL, Ngo DT, Chapman MJ, Ali OA, Chirkov YY, Horowitz JD. Pathogenesis of aortic stenosis: not just a matter of wear and tear. Am. J. Cardiovasc. Dis. 1(2), 185–199 (2011).
   PubMedGoogle Scholar
• Otto CM, Lind BK, Kitzman DW, Gersh BJ, Siscovick DS. Association of aortic-valve sclerosis with cardiovascular mortality and morbidity in the elderly. N. Engl. J. Med. 341(3), 142–147 (1999).
   PubMed Web of Science ®Google Scholar
• Novaro GM, Katz R, Aviles RJ et al. Clinical factors, but not C-reactive protein, predict progression of calcific aortic-valve disease: the Cardiovascular Health Study. J. Am. Coll. Cardiol. 50(20), 1992–1998 (2007).
   PubMed Web of Science ®Google Scholar
• Otto CM, O’Brien KD. Why is there discordance between calcific aortic stenosis and coronary artery disease? Heart 85(6), 601–602 (2001).
   Google Scholar
• Chan KL, Teo K, Dumesnil JG, Ni A, Tam J; ASTRONOMER Investigators. Effect of lipid lowering with rosuvastatin on progression of aortic stenosis: results of the aortic stenosis progression observation: measuring effects of rosuvastatin (ASTRONOMER) trial. Circulation 121(2), 306–314 (2010).
   PubMed Web of Science ®Google Scholar
• Cowell SJ, Newby DE, Prescott RJ et al.; Scottish Aortic Stenosis and Lipid Lowering Trial, Impact on Regression (SALTIRE) Investigators. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N. Engl. J. Med. 352(23), 2389–2397 (2005).
   PubMed Web of Science ®Google Scholar
• Rossebø AB, Pedersen TR, Boman K et al.; SEAS Investigators. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N. Engl. J. Med. 359(13), 1343–1356 (2008).
   PubMed Web of Science ®Google Scholar
• Helske S, Kupari M, Lindstedt KA, Kovanen PT. Aortic valve stenosis: an active atheroinflammatory process. Curr. Opin. Lipidol. 18(5), 483–491 (2007).
   PubMed Web of Science ®Google Scholar
• Fóris G, Dezsö B, Medgyesi GA, Füst G. Effect of angiotensin II on macrophage functions. Immunology 48(3), 529–535 (1983).
   PubMed Web of Science ®Google Scholar
• Otto CM, Kuusisto J, Reichenbach DD, Gown AM, O’Brien KD. Characterization of the early lesion of ‘degenerative’ valvular aortic stenosis. Histological and immunohistochemical studies. Circulation 90(2), 844–853 (1994).
   PubMed Web of Science ®Google Scholar
• Aikawa E, Nahrendorf M, Sosnovik D et al. Multimodality molecular imaging identifies proteolytic and osteogenic activities in early aortic valve disease. Circulation 115(3), 377–386 (2007).
   PubMed Web of Science ®Google Scholar
• O’Brien KD, Shavelle DM, Caulfield MT et al. Association of angiotensin-converting enzyme with low-density lipoprotein in aortic valvular lesions and in human plasma. Circulation 106(17), 2224–2230 (2002).
   PubMed Web of Science ®Google Scholar
• Helske S, Lindstedt KA, Laine M et al. Induction of local angiotensin II-producing systems in stenotic aortic valves. J. Am. Coll. Cardiol. 44(9), 1859–1866 (2004).
   PubMed Web of Science ®Google Scholar
• Helske S, Syväranta S, Kupari M et al. Possible role for mast cell-derived cathepsin G in the adverse remodelling of stenotic aortic valves. Eur. Heart J. 27(12), 1495–1504 (2006).
   PubMed Web of Science ®Google Scholar
• Helske S, Laine M, Kupari M et al. Increased expression of profibrotic neutral endopeptidase and bradykinin type 1 receptors in stenotic aortic valves. Eur. Heart J. 28(15), 1894–1903 (2007).
   PubMed Web of Science ®Google Scholar
• Fielitz J, Hein S, Mitrovic V et al. Activation of the cardiac renin–angiotensin system and increased myocardial collagen expression in human aortic valve disease. J. Am. Coll. Cardiol. 37(5), 1443–1449 (2001).
   PubMed Web of Science ®Google Scholar
• Irvine T, Kenny A. Aortic stenosis and angina with normal coronary arteries: the role of coronary flow abnormalities. Heart 78(3), 213–214 (1997).
   Google Scholar
• Gould KL, Carabello BA. Why angina in aortic stenosis with normal coronary arteriograms? Circulation 107(25), 3121–3123 (2003).
   PubMed Web of Science ®Google Scholar
• Julius BK, Spillmann M, Vassalli G, Villari B, Eberli FR, Hess OM. Angina pectoris in patients with aortic stenosis and normal coronary arteries. Mechanisms and pathophysiological concepts. Circulation 95(4), 892–898 (1997).
   PubMed Web of Science ®Google Scholar
• Villari B, Campbell SE, Hess OM et al. Influence of collagen network on left ventricular systolic and diastolic function in aortic valve disease. J. Am. Coll. Cardiol. 22(5), 1477–1484 (1993).
   PubMed Web of Science ®Google Scholar
• Vekshtein VI, Alexander RW, Yeung AC et al. Coronary atherosclerosis is associated with left ventricular dysfunction and dilatation in aortic stenosis. Circulation 82(6), 2068–2074 (1990).
   PubMed Web of Science ®Google Scholar
• Gjertsson P, Caidahl K, Farasati M, Odén A, Bech-Hanssen O. Preoperative moderate to severe diastolic dysfunction: a novel Doppler echocardiographic long-term prognostic factor in patients with severe aortic stenosis. J. Thorac. Cardiovasc. Surg. 129(4), 890–896 (2005).
   Google Scholar
• Lund O, Erlandsen M, Dørup I, Emmertsen K, Flø C, Jensen FT. Predictable changes in left ventricular mass and function during ten years after valve replacement for aortic stenosis. J. Heart Valve Dis. 13(3), 357–368 (2004).
   PubMed Web of Science ®Google Scholar
• Weinberg EO, Schoen FJ, George D et al. Angiotensin-converting enzyme inhibition prolongs survival and modifies the transition to heart failure in rats with pressure overload hypertrophy due to ascending aortic stenosis. Circulation 90(3), 1410–1422 (1994).
   PubMed Web of Science ®Google Scholar
• Linz W, Schaper J, Wiemer G, Albus U, Schölkens BA. Ramipril prevents left ventricular hypertrophy with myocardial fibrosis without blood pressure reduction: a one year study in rats. Br. J. Pharmacol. 107(4), 970–975 (1992).
   PubMed Web of Science ®Google Scholar
• Ngo DT, Stafford I, Sverdlov AL et al. Ramipril retards development of aortic valve stenosis in a rabbit model: mechanistic considerations. Br. J. Pharmacol. 162(3), 722–732 (2011).
   PubMed Web of Science ®Google Scholar
• Cox NL, Abdul-Hamid AR, Mulley GP. Why deny ACE inhibitors to patients with aortic stenosis? Lancet 352(9122), 111–112 (1998).
   Google Scholar
• Vahanian A, Baumgartner H, Bax J et al.; Task Force on the Management of Valvular Hearth Disease of the European Society of Cardiology; ESC Committee for Practice Guidelines. Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology. Eur. Heart J. 28(2), 230–268 (2007).
   PubMed Web of Science ®Google Scholar
• Martínez Sánchez C, Henne O, Arceo A et al. Hemodynamic effects of oral captopril in patients with critical aortic stenosis. Arch. Inst. Cardiol. Mex. 66(4), 322–330 (1996).
   Google Scholar
• O’Brien KD, Zhao XQ, Shavelle DM et al. Hemodynamic effects of the angiotensin-converting enzyme inhibitor, ramipril, in patients with mild to moderate aortic stenosis and preserved left ventricular function. J. Investig. Med. 52(3), 185–191 (2004).
   PubMed Web of Science ®Google Scholar
• Chockalingam A, Venkatesan S, Subramaniam T et al.; Symptomatic Cardiac Obstruction – Pilot Study of Enalapril in Aortic Stenosis. Safety and efficacy of angiotensin-converting enzyme inhibitors in symptomatic severe aortic stenosis: Symptomatic Cardiac Obstruction – Pilot Study of Enalapril in Aortic Stenosis (SCOPE-AS). Am. Heart J. 147(4), E19 (2004).
   PubMed Web of Science ®Google Scholar
• Jiménez-Candil J, Bermejo J, Yotti R et al. Effects of angiotensin converting enzyme inhibitors in hypertensive patients with aortic valve stenosis: a drug withdrawal study. Heart 91(10), 1311–1318 (2005).
   PubMed Web of Science ®Google Scholar
• Wakabayashi K, Tsujino T, Naito Y et al. Administration of angiotensin-converting enzyme inhibitors is associated with slow progression of mild aortic stenosis in Japanese patients. Heart Vessels 26(3), 252–257 (2011).
   Google Scholar
• DalsgaardM. Acute hemodynamic effects of treatment with ACE inhibitors in severe aortic valve stenosis: a placebo-controlled randomized study. L. Presented at: American College of Cardiology 60th Annual Scientific Session. New Orleans, LA, USA, 3 April 2011.
   Google Scholar
• Stewart BF, Siscovick D, Lind BK et al. Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study. J. Am. Coll. Cardiol. 29(3), 630–634 (1997).
   PubMed Web of Science ®Google Scholar
• Nadir MA, Wei L, Elder DH et al. Impact of renin–angiotensin system blockade therapy on outcome in aortic stenosis. J. Am. Coll. Cardiol. 58(6), 570–576 (2011).
   PubMed Web of Science ®Google Scholar
• Maurer G. Aortic regurgitation. Heart 92(7), 994–1000 (2006).
   PubMed Web of Science ®Google Scholar
• Scognamiglio R, Fasoli G, Ponchia A, Dalla-Volta S. Long-term nifedipine unloading therapy in asymptomatic patients with chronic severe aortic regurgitation. J. Am. Coll. Cardiol. 16(2), 424–429 (1990).
   PubMedGoogle Scholar
• Scognamiglio R, Rahimtoola SH, Fasoli G, Nistri S, Dalla Volta S. Nifedipine in asymptomatic patients with severe aortic regurgitation and normal left ventricular function. N. Engl. J. Med. 331(11), 689–694 (1994).
   PubMed Web of Science ®Google Scholar
• Chambers J. The left ventricle in aortic stenosis: evidence for the use of ACE inhibitors. Heart 92(3), 420–423 (2006).
   PubMed Web of Science ®Google Scholar
• Friedrich SP, Lorell BH, Rousseau MF et al. Intracardiac angiotensin-converting enzyme inhibition improves diastolic function in patients with left ventricular hypertrophy due to aortic stenosis. Circulation 90(6), 2761–2771 (1994).
   PubMed Web of Science ®Google Scholar
• Plante E, Lachance D, Beaudoin J et al. Comparative study of vasodilators in an animal model of chronic volume overload caused by severe aortic regurgitation. Circ. Heart Fail. 2(1), 25–32 (2009).
   Google Scholar
• Plante E, Gaudreau M, Lachance D et al. Angiotensin-converting enzyme inhibitor captopril prevents volume overload cardiomyopathy in experimental chronic aortic valve regurgitation. Can. J. Physiol. Pharmacol. 82(3), 191–199 (2004).
   Google Scholar
• Bonow RO, Carabello BA, Chatterjee K et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing Committee to Revise the 1998 guidelines for the management of patients with valvular heart disease) developed in collaboration with the Society of Cardiovascular Anesthesiologists endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. J. Am. Coll. Cardiol. 48(3), e1–e148 (2006).
   Google Scholar
• Lin M, Chiang HT, Lin SL et al. Vasodilator therapy in chronic asymptomatic aortic regurgitation: enalapril versus hydralazine therapy. J. Am. Coll. Cardiol. 24(4), 1046–1053 (1994).
   PubMedGoogle Scholar
• Banaszewski M, Rydlewska-Sadowska W, Rubkiewicz S. Captopril or nifedipine? Comparison of rest and exercise acute effects and long-term therapy in chronic isolated asymptomatic moderate to severe aortic regurgitation. J. Heart Valve Dis. 7(5), 488–499 (1998).
   Google Scholar
• Evangelista A, Tornos P, Sambola A, Permanyer-Miralda G, Soler-Soler J. Long-term vasodilator therapy in patients with severe aortic regurgitation. N. Engl. J. Med. 353(13), 1342–1349 (2005).
   PubMed Web of Science ®Google Scholar
• Elder DH, Wei L, Szwejkowski BR et al. The impact of renin–angiotensin-aldosterone system blockade on heart failure outcomes and mortality in patients identified to have aortic regurgitation: a large population cohort study. J. Am. Coll. Cardiol. 58(20), 2084–2091 (2011).
   PubMedGoogle Scholar
• Oliver JM, Alonso-Gonzalez R, Gonzalez AE et al. Risk of aortic root or ascending aorta complications in patients with bicuspid aortic valve with and without coarctation of the aorta. Am. J. Cardiol. 104(7), 1001–1006 (2009).
   PubMed Web of Science ®Google Scholar
• Fernández B, Durán AC, Fernández-Gallego T et al. Bicuspid aortic valves with different spatial orientations of the leaflets are distinct etiological entities. J. Am. Coll. Cardiol. 54(24), 2312–2318 (2009).
   Web of Science ®Google Scholar
• Kumpuris AG, Quinones MA, Waggoner AD, Kanon DJ, Nelson JG, Miller RR. Importance of preoperative hypertrophy, wall stress and end-systolic dimension as echocardiographic predictors of normalization of left ventricular dilatation after valve replacement in chronic aortic insufficiency. Am. J. Cardiol. 49(5), 1091–1100 (1982).
   PubMed Web of Science ®Google Scholar
• Carroll JD, Gaasch WH, Zile MR, Levine HJ. Serial changes in left ventricular function after correction of chronic aortic regurgitation. Dependence on early changes in preload and subsequent regression of hypertrophy. Am. J. Cardiol. 51(3), 476–482 (1983).
   PubMed Web of Science ®Google Scholar
• Wisenbaugh T, Sinovich V, Dullabh A, Sareli P. Six month pilot study of captopril for mildly symptomatic, severe isolated mitral and isolated aortic regurgitation. J. Heart Valve Dis. 3(2), 197–204 (1994).
   PubMedGoogle Scholar
• Schon HR, Dorn R, Barthel P, Schomig A. Effects of 12 months quinapril therapy in asymptomatic patients with chronic aortic regurgitation. J. Heart Valve Dis. 3(5), 500–509 (1994).
   PubMedGoogle Scholar